Khartis Therapeutics Raises $50M Series B

Khartis Therapeutics has emerged from stealth with a $50M Series B financing led by Forge Life Science Partners. Longwood Fund and Alexandria Venture Investments participated alongside returning investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing Khartis' total capital raised to $95M.

The San Diego biotech is using the money to advance an oral, selective inhibitor of insulin-like growth factor 1 receptor, or IGF-1R, for thyroid eye disease. Khartis describes the program as the first oral, selective IGF-1R inhibitor designed specifically for the condition, while the round also supports a broader pipeline of oral small molecules aimed at clinically validated immunology pathways.

The broader implication is easy to miss if this is treated as another financing notice. Khartis is not asking investors to believe in an untested biological target. It is trying to change the drug format around a target that has already produced an approved therapy, then prove that a selective small molecule can create a useful clinical alternative.

What Khartis Raised and Who Backed It

The Series B adds three new investors to the Khartis syndicate. Forge Life Science Partners led the financing, while Longwood Fund and Alexandria Venture Investments joined the round. Foresite Capital, Lilly Asia Ventures, and Nextech Invest returned after backing the company's earlier financing.

Khartis did not disclose a valuation or provide a separate amount for its prior round. The company said only that the new $50M financing brings total capital raised to $95M, so labeling the precise size of the earlier round would require inference rather than direct disclosure. That distinction matters because funding histories have a bad habit of turning arithmetic into “fact” after enough databases repeat it.

The investor composition is still informative. A new lead gives Khartis fresh external validation, while the returning investors have had time to observe the team and its early progress. That does not remove development risk, but it does show continued financial support as the company moves from formation and discovery toward the clinic.

Why the IGF-1R Strategy Matters

Thyroid eye disease is an autoimmune condition that can inflame muscles, fat, and other tissue around and behind the eyes. The disease can cause eye bulging, double vision, pain, swelling, and, in severe cases, vision-threatening complications, making treatment burden more than a scheduling inconvenience.

IGF-1R is already a clinically validated target in thyroid eye disease. Tepezza's FDA prescribing information identifies teprotumumab as an IGF-1R inhibitor and calls for eight intravenous infusions. The label also identifies risks and monitoring considerations that include hyperglycemia, hearing impairment, and infusion reactions.

Khartis is not claiming that its program has already solved those problems. The company is advancing toward the clinic and has not disclosed a candidate name, human data, dosing schedule, clinical timeline, or comparative safety results. Its thesis is narrower and more credible at this stage: an oral, selective small molecule may offer a more patient-friendly way to act on a proven target if the molecule can clear the usual safety, pharmacology, and efficacy hurdles.

A Team Built Around Small-Molecule Discovery

Khartis was founded by Robert Hoffman, CEO and Head of Drug Discovery; Craig Murphy, CSO; and Chris LeMasters, Executive Chairman. The company's newest financing announcement dates its founding to 2024, while current founder biographies describe the company as co-founded in 2023. Khartis has not reconciled the difference, so the discrepancy is best preserved rather than resolved through inference.

The founders and many members of the scientific team previously worked together at XinThera. Gilead Sciences acquired XinThera in May 2023, adding precision small-molecule programs focused on oncology and inflammation. That shared history gives Khartis a team that has already operated through discovery, company building, and an acquisition.

Experience is not a substitute for data, especially in drug development. It does, however, reduce one common source of startup uncertainty: whether the team can work together when the chemistry stops cooperating, the timeline slips, or a program forces a hard decision. Khartis enters this financing with more operating continuity than a newly assembled group would have.

What the $50M Needs to Accomplish

Khartis says the proceeds will move the lead thyroid eye disease program toward the clinic and continue development of its wider oral immunology pipeline. The company has not announced an investigational new drug filing date, first-in-human trial schedule, hiring target, or formal product roadmap, so the next meaningful proof points will have to come from development progress rather than financing language.

The immediate challenge is converting a clear formulation thesis into a development-grade medicine. Oral delivery can improve convenience, but convenience alone does not establish efficacy, durability, selectivity, or safety. Khartis must show that its molecule reaches the right exposure, produces the intended biological effect, and supports a risk-benefit profile that justifies clinical testing.

The wider pipeline also bears watching because Khartis is positioning the lead program as the first expression of a repeatable small-molecule discovery capability. If the company can translate clinically validated immunology pathways into differentiated oral medicines, the platform value could extend beyond thyroid eye disease. If it cannot, the Series B will remain a well-funded hypothesis built around one program.

What This Financing Signals

Khartis sits at an interesting point in biotech financing. Investors are still willing to fund preclinical drug developers, but the strongest stories increasingly combine known biology, experienced teams, and a differentiated development angle instead of asking capital to finance discovery theater.

This round checks those boxes without removing the hard part. The target has clinical validation, the team has shared small-molecule experience, and the oral-selective thesis is easy to understand. What remains unknown is whether Khartis can turn that thesis into a candidate that performs well enough to matter in humans.

The $50M Series B is more than a stealth reveal but less than a victory lap. Khartis now has $95M in total backing and a clear mandate to advance its lead program. The next chapter belongs to the data, which is where every biotech story eventually loses the lighting crew and meets the molecule.